Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GANCICLOVIR vs ACYCLOVIR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).
Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.
Treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including AIDS patients.,Prevention of CMV disease in transplant recipients at risk.,Treatment of CMV pneumonitis, colitis, esophagitis, and other CMV infections in immunocompromised patients (off-label).,Treatment of herpes simplex virus (HSV) infections resistant to acyclovir (off-label).
Herpes simplex virus (HSV) infections: genital herpes, herpes labialis, herpes simplex encephalitis, neonatal herpes,Varicella-zoster virus (VZV) infections: chickenpox, herpes zoster (shingles),Mucocutaneous HSV infections in immunocompromised patients,Prophylaxis of HSV and VZV infections in immunocompromised patients
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.
400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.
Terminal half-life: 2.5-5.0 hours in normal renal function; prolonged to 10-30 hours in renal impairment; requires dose adjustment for Cr Cl <70 m L/min
Terminal elimination half-life is 2.5–3.3 hours in adults with normal renal function; increases to 19.5 hours in anuria.
Ganciclovir is not significantly metabolized; it is primarily excreted unchanged by the kidneys via glomerular filtration and active tubular secretion. Less than 1% is metabolized to 9-[(1,3-dihydroxy-2-propoxymethyl)guanine].
Acyclovir is partially metabolized by alcohol and aldehyde dehydrogenase. The major metabolite is 9-carboxymethoxymethylguanine (CMMG), which is inactive. Hepatic metabolism is minimal, and the drug is predominantly excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal excretion: >90% unchanged; biliary/fecal: minimal (<5%)
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 62-90% of elimination. Fecal elimination is <2%.
1-2% bound; primarily to albumin (low binding)
9–33% bound to plasma proteins (albumin).
0.47-0.74 L/kg; indicates extensive distribution into tissues including brain, eye, and lungs
Vd: 0.5–1.5 L/kg. Distributes widely; crosses blood-brain barrier achieving 50% of plasma CSF concentration.
Oral: 6-9% (fasting); increased to 30% with food due to enhanced absorption
Oral: 15–30% (dose-dependent). Topical: Minimal systemic absorption (<5%).
Cr Cl ≥70 m L/min: 5 mg/kg q12h (induction), 5 mg/kg q24h (maintenance); Cr Cl 50-69: 2.5 mg/kg q12h, then 2.5 mg/kg q24h; Cr Cl 25-49: 2.5 mg/kg q24h, then 1.25 mg/kg q24h; Cr Cl 10-24: 1.25 mg/kg q24h, then 0.625 mg/kg q24h; Cr Cl <10: 1.25 mg/kg 3 times/week after hemodialysis. Oral: Cr Cl ≥70: 1000 mg tid; 50-69: 1500 mg qd or 500 mg tid; 25-49: 1000 mg qd or 500 mg bid; 10-24: 500 mg qd; <10: 500 mg 3 times/week after dialysis.
Cr Cl >25 m L/min: no adjustment; Cr Cl 10-25 m L/min: standard dose every 12 hours; Cr Cl <10 m L/min: standard dose every 24 hours.
No dose adjustment required for hepatic impairment. Use with caution in severe hepatic dysfunction due to limited data.
No dose adjustment required for hepatic impairment; no Child-Pugh based modifications established.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral dosing in children ≥9 years: 1000 mg three times daily with food; for children <9 years, use weight-based: 30 mg/kg per dose (max 1000 mg) three times daily.
Neonates: 10-20 mg/kg intravenously every 8 hours; Children: 250-600 mg/m² orally 3-5 times daily or 5-10 mg/kg intravenously every 8 hours.
No specific dose adjustments beyond renal function. Closely monitor renal function and adjust dose based on Cr Cl.
Adjust based on renal function; start at low end of dosing range; monitor for neurotoxicity.
Ganciclovir is associated with granulocytopenia, anemia, and thrombocytopenia. Animal studies have shown that ganciclovir is carcinogenic, mutagenic, and causes impairment of fertility and teratogenicity. It is indicated only for the treatment of CMV retinitis and prevention of CMV disease in transplant recipients. Not approved for congenital or neonatal CMV disease.
None. Acyclovir does not have a black box warning.
Hematologic toxicity: Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, and bone marrow suppression, especially in patients with pre-existing cytopenias or on concomitant myelosuppressive drugs.,Renal impairment: Dose adjustment required; increased risk of toxicity in renal dysfunction.,Carcinogenicity and mutagenicity: Anticipated in humans based on animal data.,Teratogenicity: Embryotoxic and teratogenic in animals; use only if benefit outweighs risk.,Interaction with mycophenolate mofetil: May increase risk of hematologic toxicity.,Electrolyte disturbances: May cause hypocalcemia, hypokalemia, hyponatremia.,Ocular effects: Retinal detachment in patients with CMV retinitis (not directly drug-related).,Seizures and neurotoxicity: Rare, especially in patients with CNS conditions or renal impairment.
Renal impairment: Dose adjustment required for Cr Cl < 50 m L/min; risk of acute renal failure due to crystallization in renal tubules, especially with rapid IV infusion or dehydration,Neurologic toxicity: Elderly patients or those with renal impairment may develop CNS effects (agitation, hallucinations, seizures); use with caution,Hematologic: Rare reports of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in immunocompromised patients,IV administration: Avoid rapid infusion, ensure adequate hydration to prevent renal damage
Hypersensitivity to ganciclovir, valganciclovir, or any component of the formulation.,Absolute neutrophil count < 500 cells/μL, platelet count < 25,000/μL, or hemoglobin < 8 g/d L (relative contraindication due to risk of worsening cytopenias).,Pregnancy (avoid unless potential benefit outweighs risk; embryotoxic in animals).
Hypersensitivity to acyclovir or valacyclovir,Lactation: Caution advised; excreted in breast milk
Take ganciclovir with food to reduce gastrointestinal upset. Avoid grapefruit juice as it may increase drug levels (weak interaction). No specific food restrictions otherwise.
No significant food interactions. High-fat meals may reduce absorption but not clinically significant. Avoid excessive alcohol as it may worsen side effects (e.g., dizziness).
FDA Pregnancy Category B. Animal studies show teratogenicity (e.g., cleft palate, anophthalmia) at doses near human exposure. Human data limited; avoid first trimester unless benefit outweighs risk. Second/third trimester: potential for bone marrow suppression and nephrotoxicity in fetus; use only if clearly needed.
Acyclovir is generally considered low risk during pregnancy. Data from the Acyclovir Pregnancy Registry and postmarketing studies do not show an increased risk of major birth defects compared to the general population. However, high-dose IV acyclovir in first trimester for severe infections carries theoretical risk; use only if clearly needed. No known specific fetal risks by trimester beyond those of the underlying infection.
Not recommended. M/P ratio unknown; ganciclovir is excreted into breast milk in rats. Potential for severe adverse effects in nursing infant (e.g., bone marrow suppression, carcinogenesis).
Acyclovir is excreted into breast milk with a milk-to-plasma ratio (M/P) of approximately 0.6 to 4.1. An exclusively breastfed infant would receive 0.1-1% of maternal dose (or 0.3-0.7 mg/kg/day based on typical maternal 200 mg oral dose), which is below neonatal therapeutic doses. American Academy of Pediatrics considers acyclovir compatible with breastfeeding. Monitor infant for rash or gastrointestinal disturbance.
No specific pregnancy dosing adjustments established. Pharmacokinetics may be altered due to increased plasma volume and renal clearance; monitor drug levels if available. Standard dosing: 5 mg/kg IV q12h x 14-21 days (induction), then 5 mg/kg/day (maintenance). Adjust for renal function (Cr Cl). Use lowest effective dose.
Pregnancy does not significantly alter acyclovir pharmacokinetics; no dose adjustment needed for oral or IV acyclovir. Standard dosing regimens for HSV (e.g., 200-400 mg PO TID for genital herpes or 5-10 mg/kg IV q8h for severe infection) are used. In third trimester, increased renal clearance may require slightly higher doses for VZV (typically 800 mg PO 5 times/day), but no formal recommendations for dose increase. Always adjust for renal impairment separately.
Monitor renal function closely; dose adjustment required in renal impairment. Ganciclovir is myelosuppressive; check CBC frequently, especially in patients with neutropenia. Use with caution in patients with pre-existing cytopenias. Administer IV infusion over at least 1 hour to reduce renal toxicity. Valganciclovir, the prodrug, is only for CMV retinitis in immunocompromised patients. Always maintain adequate hydration to prevent crystalluria.
Acyclovir requires adequate hydration to prevent crystalluria and nephrotoxicity; ensure urine output >500 m L/q8h. For IV acyclovir, infuse over at least 1 hour to avoid renal damage. Dose adjustment required in renal impairment (Cr Cl <50 m L/min). Early initiation (within 72 hours of rash) improves outcomes in herpes zoster. Oral acyclovir has low bioavailability (15-30%); valacyclovir is a prodrug with better absorption.
Take this medication exactly as prescribed; do not skip doses or stop without consulting your doctor.,Ganciclovir may lower your blood cell counts, increasing risk of infection, bleeding, or anemia. Report any signs of infection (fever, chills), unusual bruising/bleeding, or fatigue immediately.,Keep all appointments for blood tests and kidney function monitoring.,Drink plenty of fluids to prevent kidney problems.,Use effective contraception during treatment and for at least 30 days after stopping for females, and for 90 days for males; ganciclovir can harm an unborn baby.,Do not breastfeed during treatment due to potential harm to the infant.,Avoid driving or operating machinery if you experience dizziness, confusion, or seizures.
Take acyclovir exactly as prescribed, even if symptoms improve.,Drink plenty of water during treatment to prevent kidney problems.,Start medication at the first sign of outbreak for best results.,Do not share your medication with others.,Avoid sexual contact when lesions are present to prevent transmission.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Probenecid inhibits renal tubular secretion of ganciclovir, reducing its clearance and increasing its plasma concentration. This can potentiate the antiviral effect but also elevates the risk of dose-dependent adverse effects such as myelosuppression and nephrotoxicity. Concurrent use may require dose adjustment of ganciclovir and monitoring for toxicity."
"Combined use of ganciclovir and zidovudine results in additive myelosuppression, particularly neutropenia and anemia, due to overlapping bone marrow toxicity. This interaction increases the risk of severe hematologic adverse effects, including life-threatening infections and transfusion-dependent anemia. Patients with pre-existing cytopenias or those receiving other myelotoxic agents are at heightened risk."
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Zalcitabine."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GANCICLOVIR vs ACYCLOVIR, answered by our medical review team.
GANCICLOVIR is a Antiviral that works by Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).. ACYCLOVIR is a Antiviral that works by Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GANCICLOVIR and ACYCLOVIR depend on the specific clinical indication. These are both Antiviral agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GANCICLOVIR is: Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.. The standard adult dose of ACYCLOVIR is: 400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GANCICLOVIR and ACYCLOVIR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GANCICLOVIR is classified as Category D/X. FDA Pregnancy Category B. Animal studies show teratogenicity (e.g., cleft palate, anophthalmia) at doses near human exposure. Human data limited; avoid first trimester unless benef. ACYCLOVIR is classified as Category A/B. Acyclovir is generally considered low risk during pregnancy. Data from the Acyclovir Pregnancy Registry and postmarketing studies do not show an increased risk of major birth defec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.